TY - JOUR
T1 - Increased plasma macrophage inflammatory protein (MIP)-1 alpha and MIP-1 beta levels in type 1 Gaucher disease
AU - van Breemen, Marielle J.
AU - de Fost, Maaike
AU - Voerman, Jane S. A.
AU - Laman, Jon D.
AU - Boot, Rolf G.
AU - Maas, Mario
AU - Hollak, Carla E. M.
AU - Aerts, Johannes M.
AU - Rezaee, Farhad
PY - 2007
Y1 - 2007
N2 - Pancytopenia, hepatosplenomegaly and skeletal complications are hallmarks of Gaucher disease. Monitoring of the outcome of therapy on skeletal status of Gaucher patients is problematic since currently available imaging techniques are expensive and not widely accessible. The availability of a blood test that relates to skeletal manifestations would be very valuable. We here report that macrophage inflammatory protein (MIP)-1 alpha and MIP-1 beta, both implicated in skeletal complications in multiple myeloma (MM), are significantly elevated in plasma of Gaucher patients. Plasma MIP-1 alpha of patients (median 78 pg/ml, range 21-550 pg/ml, n = 48) is elevated (normal median 9 pg/ml, range 0-208 pg/ml, n = 39). Plasma MIP-1 beta of patients (median 201 pg/ml, range 59-647 pg/ml, n = 49) is even more pronouncedly increased (non-nal median 17 pg/ ml, range 1-41 pg/ml, n = 39; one outlier: 122 pg/ml). The increase in plasma MIP-1 beta levels of Gaucher patients is associated with skeletal disease. The plasma levels of both chemokines decrease upon effective therapy. Lack of reduction of plasma MIP-1 beta below 85 pg/ml during 5 years of therapy was observed in patients with ongoing skeletal disease. In conclusion, MIP-1 alpha and MIP-1 beta are elevated in plasma of Gaucher patients and remaining high levels of MIP-1 beta during therapy seem associated with ongoing skeletal disease. (c) 2007 Elsevier B.V. All rights reserved
AB - Pancytopenia, hepatosplenomegaly and skeletal complications are hallmarks of Gaucher disease. Monitoring of the outcome of therapy on skeletal status of Gaucher patients is problematic since currently available imaging techniques are expensive and not widely accessible. The availability of a blood test that relates to skeletal manifestations would be very valuable. We here report that macrophage inflammatory protein (MIP)-1 alpha and MIP-1 beta, both implicated in skeletal complications in multiple myeloma (MM), are significantly elevated in plasma of Gaucher patients. Plasma MIP-1 alpha of patients (median 78 pg/ml, range 21-550 pg/ml, n = 48) is elevated (normal median 9 pg/ml, range 0-208 pg/ml, n = 39). Plasma MIP-1 beta of patients (median 201 pg/ml, range 59-647 pg/ml, n = 49) is even more pronouncedly increased (non-nal median 17 pg/ ml, range 1-41 pg/ml, n = 39; one outlier: 122 pg/ml). The increase in plasma MIP-1 beta levels of Gaucher patients is associated with skeletal disease. The plasma levels of both chemokines decrease upon effective therapy. Lack of reduction of plasma MIP-1 beta below 85 pg/ml during 5 years of therapy was observed in patients with ongoing skeletal disease. In conclusion, MIP-1 alpha and MIP-1 beta are elevated in plasma of Gaucher patients and remaining high levels of MIP-1 beta during therapy seem associated with ongoing skeletal disease. (c) 2007 Elsevier B.V. All rights reserved
U2 - https://doi.org/10.1016/j.bbadis.2007.04.002
DO - https://doi.org/10.1016/j.bbadis.2007.04.002
M3 - Article
C2 - 17499484
SN - 0925-4439
VL - 1772
SP - 788
EP - 796
JO - Biochimica et Biophysica Acta-Molecular Basis of Disease
JF - Biochimica et Biophysica Acta-Molecular Basis of Disease
IS - 7
ER -